Kovaltry

Octocog alfa, the active ingredient in Kovaltry, is a recombinant factor VIII concentrate presented as a lyophilized powder for solution for injection for intravenous use. It replaces deficient factor VIII in patients with hemophilia A, helping to restore normal clotting.

GNH USA supplies Kovaltry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. Clients benefit from comprehensive regulatory support and timely delivery across global markets.

Kovaltry is used in the management of hemophilia A, a congenital deficiency of coagulation factor VIII. - Prophylaxis of bleeding episodes in patients with hemophilia A: reduces the frequency of spontaneous bleeds. - On‑demand treatment of acute bleeding episodes in hemophilia A: rapidly stops active bleeding. - Perioperative management of patients with hemophilia A: provides hemostasis during surgical procedures.

Adverse reactions to Kovaltry may vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema - Headache - Fever - Fatigue

Serious or Rare Side Effects: - Development of inhibitors (antibodies) against factor VIII - Anaphylactic or severe hypersensitivity reactions - Thromboembolic events such as deep‑vein thrombosis

When using Kovaltry, several precautions should be observed to ensure safety and efficacy. - Individualized dosing: dose is calculated based on patient’s factor VIII activity levels and clinical response. - Inhibitor monitoring: regularly test for anti‑factor VIII antibodies, especially after repeated exposure. - Hypersensitivity risk: avoid use in patients with known allergy to any component of the product. - Surgical procedures: confirm adequate factor VIII levels before and after surgery to maintain hemostasis. - Pregnancy and lactation: limited data; weigh potential benefits against unknown risks before administration. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Kovaltry may interact with other agents that affect hemostasis or immune response.

Major Interactions (Avoid): - Bypassing agents such as activated prothrombin complex concentrate: concurrent use can increase thrombotic risk. - Immune tolerance induction regimens: may interfere with inhibitor testing and alter efficacy.

Moderate Interactions (Monitor Closely): - Antifibrinolytics (e.g., tranexamic acid): may enhance clot stability; monitor for excessive thrombosis. - Live vaccines: immune response may be altered; assess timing relative to factor VIII administration. - Concomitant anticoagulants: may diminish overall hemostatic effect; monitor coagulation parameters.